诺和诺德将以2亿美元的价格收购Novavax在捷克共和国的制造工厂-动脉网

Wegovy Maker Novo Nordisk To Buy Novavax's Czech Republic Manufacturing Facility For $200 Million

benzinga 等信源发布 2024-12-04 13:39



可切换为仅中文







On Wednesday, Novavax, Inc. NVAX agreed to sell its Bohumil, Czech Republic manufacturing facility to Novo Nordisk A/S NVO for $200 million.

周三，Novavax，Inc.NVAX同意以2亿美元的价格将其位于捷克共和国博胡米尔的制造工厂出售给诺和诺德公司。

The agreement includes transferring assets, including a 150,000-square-foot recombinant protein manufacturing facility with support buildings, the existing workforce, and all related and required infrastructure.

该协议包括转让资产，包括一个15万平方英尺的重组蛋白生产设施，以及配套大楼、现有劳动力以及所有相关和必要的基础设施。

Also Read: FDA Gives Green Signal To Novavax’s COVID-19-Influenza Combo Vaccine Late-Stage Trial

The agreement provides Novavax with significant, non-dilutive capital, further enabling the company to advance its corporate growth strategy and drive value from its early—and late-stage pipeline using its proven technology platform, which consists of Matrix-M adjuvant and nanoparticle protein-based technology..

该协议为Novax提供了大量非稀释性资本，进一步使该公司能够利用其成熟的技术平台（由Matrix-M佐剂和基于纳米颗粒蛋白质的技术组成）推进其公司增长战略，并从其早期和晚期管道中推动价值。。

In addition to the $190 million cash payment in 2024 and an additional $10 million in 2025, Novavax expects the sale of the facility to result in annual operating cost reductions of approximately $80 million.

除了2024年支付1.9亿美元现金和2025年额外支付1000万美元外，Novavax预计该设施的出售将导致年度运营成本降低约8000万美元。

“The decision to sell the Czech Republic manufacturing facility aligns with our previously announced commitment to evolve Novavax into a more lean and agile organization focused on partnering our pipeline assets and technology platform,” said John C. Jacobs, President and Chief Executive Officer, Novavax..

Novavax总裁兼首席执行官John C.Jacobs表示：“出售捷克共和国制造工厂的决定符合我们先前宣布的将Novavax发展成为一个更加精益和灵活的组织的承诺，该组织专注于与我们的管道资产和技术平台合作。”。。

Last month, Novavax lowered its 2024 revenue guidance to $650 million—$700 million, compared to prior guidance of $700 million—$800 million and a consensus of $761.5 million.

上个月，Novavax将其2024年的收入预期下调至6.5亿美元至7亿美元，而之前的预期为7亿美元至8亿美元，一致认为为7.615亿美元。

Price Action: NVAX stock is down 2.32% at $8.215 at the last check on Wednesday.

价格走势：周三，NVAX股价下跌2.32%，至8.215美元。